Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?

Sadanandam A, Lal A, Benz SC, Eppenberger-Castori S, Scott G, Gray JW, Spellman P, Waldman F, Benz CC.

Breast Cancer Res Treat. 2012 Dec;136(3):693-703. doi: 10.1007/s10549-012-2290-3. Epub 2012 Oct 27.


Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Baldetorp B, Borg A.

Breast Cancer Res. 2011;13(6):R129. doi: 10.1186/bcr3075. Epub 2011 Dec 14.


Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.

Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R.

Oncotarget. 2017 Feb 14;8(7):10845-10857. doi: 10.18632/oncotarget.14802.


High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R25. doi: 10.1186/bcr2568. Epub 2010 May 6.


Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.

Jang MH, Kim EJ, Kim HJ, Chung YR, Park SY.

Breast Cancer Res Treat. 2015 Aug;153(1):67-77. doi: 10.1007/s10549-015-3522-0. Epub 2015 Jul 30.


Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.

Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S, Kim J, McCaskill C, Lim L, Gorre M, Mohammed M.

BMC Cancer. 2010 Jul 28;10:396. doi: 10.1186/1471-2407-10-396.


Close/positive margins after breast-conserving therapy: additional resection or no resection?

Wood WC.

Breast. 2013 Aug;22 Suppl 2:S115-7. doi: 10.1016/j.breast.2013.07.022. Review.


HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.

Panvichian R, Tantiwetrueangdet A, Wongwaisayawan S, Nampoon A, Lertsithichai P, Leelaudomlipi S.

Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):367-74. doi: 10.1097/PAI.0b013e31823fc207.


Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.

Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA.

Cancer Res. 2002 Mar 15;62(6):1676-81.


Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer.

Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML.

PLoS One. 2011;6(8):e23543. doi: 10.1371/journal.pone.0023543. Epub 2011 Aug 12.


Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.

Afzal M, Amir M, Hassan MJ, Hussain MS, Aziz MN, Murad S, Murtaza I, Anees M, Sultan A.

Tumour Biol. 2016 Jul;37(7):8665-72. doi: 10.1007/s13277-015-4657-7. Epub 2016 Jan 6. Erratum in: Tumour Biol. 2016 Sep 30;:.


Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors.

Heaphy CM, Bisoffi M, Fordyce CA, Haaland CM, Hines WC, Joste NE, Griffith JK.

Int J Cancer. 2006 Jul 1;119(1):108-16.


Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.

Zhu Y, Lu D, Lira ME, Xu Q, Du Y, Xiong J, Mao M, Chung HC, Zheng G.

Exp Mol Pathol. 2016 Apr;100(2):287-93. doi: 10.1016/j.yexmp.2015.11.027. Epub 2015 Nov 25.


The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors.

Tina E, Lindqvist BM, Gabrielson M, Lubovac Z, Wegman P, Wingren S.

BMC Cancer. 2012 Aug 10;12:350. doi: 10.1186/1471-2407-12-350.


Array comparative genomic hybridisation (aCGH) analysis of premenopausal breast cancers from a nuclear fallout area and matched cases from Western New York.

Varma G, Varma R, Huang H, Pryshchepava A, Groth J, Fleming D, Nowak NJ, McQuaid D, Conroy J, Mahoney M, Moysich K, Falkner KL, Geradts J.

Br J Cancer. 2005 Sep 19;93(6):699-708.


Mammary field cancerization: molecular evidence and clinical importance.

Heaphy CM, Griffith JK, Bisoffi M.

Breast Cancer Res Treat. 2009 Nov;118(2):229-39. doi: 10.1007/s10549-009-0504-0. Epub 2009 Aug 15. Review.


Genomic Characterization of Primary Invasive Lobular Breast Cancer.

Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C.

J Clin Oncol. 2016 Jun 1;34(16):1872-81. doi: 10.1200/JCO.2015.64.0334. Epub 2016 Feb 29.


[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].

Zeng X, Liang ZY, Wu SF, Zhou WX, Gao J, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Chinese.


Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Tsuji K, Kawauchi S, Saito S, Furuya T, Ikemoto K, Nakao M, Yamamoto S, Oka M, Hirano T, Sasaki K.

BMC Cancer. 2010 Jan 14;10:15. doi: 10.1186/1471-2407-10-15.


Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.

Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Dimopoulos MA.

BMC Cancer. 2013 Mar 28;13:163. doi: 10.1186/1471-2407-13-163.

Supplemental Content

Support Center